This is a prospective, multicenter clinical trial to assess the efficacy and the safety of the STARflo™ Glaucoma Implant.
Patients will enter the study after providing written informed consent. Patients will be screened to confirm that they are eligible for study participation.
When eligibility has been established using the in/exclusion criteria, surgery will be scheduled.
Pre and post-surgery, patients will be evaluated at scheduled intervals (1 day, 1 week, 1 month, 3 months, 6 months, 12 months, 24 months) for a total duration of 24 months following surgery.
